175 related articles for article (PubMed ID: 15753966)
1. Technological advances in adoptive immunotherapy.
Oelke M; Krueger C; Schneck JP
Drugs Today (Barc); 2005 Jan; 41(1):13-21. PubMed ID: 15753966
[TBL] [Abstract][Full Text] [Related]
2. Artificial antigen-presenting cells: artificial solutions for real diseases.
Oelke M; Krueger C; Giuntoli RL; Schneck JP
Trends Mol Med; 2005 Sep; 11(9):412-20. PubMed ID: 16103011
[TBL] [Abstract][Full Text] [Related]
3. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
4. HLA-Class II Artificial Antigen Presenting Cells in CD4
Couture A; Garnier A; Docagne F; Boyer O; Vivien D; Le-Mauff B; Latouche JB; Toutirais O
Front Immunol; 2019; 10():1081. PubMed ID: 31156634
[TBL] [Abstract][Full Text] [Related]
5. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
6. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
[TBL] [Abstract][Full Text] [Related]
8. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.
Foster AE; Gottlieb DJ; Marangolo M; Bartlett A; Li YC; Barton GW; Romagnoli JA; Bradstock KF
J Hematother Stem Cell Res; 2003 Feb; 12(1):93-105. PubMed ID: 12662440
[TBL] [Abstract][Full Text] [Related]
9. Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy.
Kammula US; Serrano OK
J Transl Med; 2008 Oct; 6():60. PubMed ID: 18937837
[TBL] [Abstract][Full Text] [Related]
10. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
11. Quality and quantity: new strategies to improve immunotherapy of cancer.
Krueger C; Schneck JP; Oelke M
Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
[TBL] [Abstract][Full Text] [Related]
12. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
13. Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo.
Laumbacher B; Gu S; Wank R
Scand J Immunol; 2012 Mar; 75(3):314-28. PubMed ID: 21995310
[TBL] [Abstract][Full Text] [Related]
14. Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD.
D'Orsogna LJ; Roelen DL; Doxiadis II; Claas FH
Transpl Immunol; 2011 Apr; 24(3):141. PubMed ID: 21167283
[No Abstract] [Full Text] [Related]
15. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.
Hammer MH; Meyer S; Brestrich G; Moosmann A; Kern F; Tesfa L; Babel N; Mittenzweig A; Rooney CM; Hammerschmidt W; Volk HD; Reinke P
Eur J Immunol; 2005 Jul; 35(7):2250-8. PubMed ID: 15915543
[TBL] [Abstract][Full Text] [Related]
16. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
17. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
18. Potential advantages of CD1-restricted T cell immunotherapy in cancer.
Consonni M; Dellabona P; Casorati G
Mol Immunol; 2018 Nov; 103():200-208. PubMed ID: 30308433
[TBL] [Abstract][Full Text] [Related]
19. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
20. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]